## Continues to deliver ahead of expectations

- Voltas saw strong revenue growth across segments in Q3, beating our estimates by 10$37 \%$. UCP revenue growth of $40 \%$ yoy (ahead of listed peers) in a seasonally lean quarter reflects channel filling ahead of price increases initiated in Jan'21.
- Revenue growth of $26 \%$ in the Projects business was a positive surprise, while margins were compressed by legacy project-based ECL provisioning. UCP EBIT growth and margin expansion ( +235 bps yoy) compensated for the weakness in EMPS.
- Due to commodity price inflation, Voltas has effected 5-6\% price increases across UCP product categories. Favourable summers \& sustained consumer demand will keep outperformance intact. Order book of $\sim$ Rs 73 bn continues to remain healthy.
- Given the strong Q3 print, we raise estimates across business segments, leading to 720\% earnings upgrade for FY21-23E. Maintain Hold, with a revised FY23E SoTP-based TP of Rs1,100, as we raise the target multiple for UCP business to 48 x from 40x.

UCP drives margin expansion: Revenue growth of $33.6 \%$ yoy to Rs19.9bn was driven by strong topline performance across business segments. Volume-led revenue growth in the UCP business (+39.8\% yoy), pick-up in execution on a low base of EMPS (+25.8\% yoy) and $46.4 \%$ yoy growth in EPS revenue have driven this strong outperformance. EBITDA margin expanded 78 bps yoy to $7.3 \%$ as EBITDA stood at Rs 1.5 bn ( $+49.6 \%$ yoy). Despite strong revenue growth, employee cost was down 11\% yoy. While ETR was lower (22.4\% in Q3FY21 vs. $26.3 \%$ in Q3FY20), JV losses widened qoq to Rs201mn (Rs71mn in Q2FY21), which can be attributable to higher spends during festive period. PAT grew $46.3 \%$ yoy to Rs1.3bn.

Outlook: Voltas has been surprising positively with strong execution across business segments after Covid-19-related disruptions. Market share gains in 9MFY21 and continuous outperformance on a high base underscores the company's robust execution capabilities. A favorable upcoming summer season, market share gains, benign base (Q1FY21) and strong execution should continue to drive Voltas ahead of industry growth. The EMPS business has seen better-than-expected recovery on revenues, while provisions for legacy orders have been impacting profitability from the last five quarters. We are penciling a gradual margin recovery in EMPS and factor in 7\% margins (lower than FY19 levels) in FY23. The order book remains robust at Rs72.7bn, providing strong revenue visibility. Voltas-Beko's focus is on maximizing production to meet increasing demand for DC refrigerators and plans are in place to start manufacturing frost-free refrigerators in the coming months, followed by top-load fully automatic washing machines as well as dishwashers. Expensive valuations restrict us for rating upgrade. Key risks: sustained market share gains in RACs; better-than-estimated performance of Volt-Bek; lower-than-estimated impact in the projects business; sustained commodity inflation and macroeconomic slowdown.

Please see our sector model portfolio (Emkay Alpha Portfolio): Consumer Durables (Page 10)
Financial Snapshot (Consolidated)

| (Rs mn) | FY19 | FY20 | FY21E | FY22E | FY23E |
| :--- | ---: | ---: | ---: | ---: | ---: |
| Revenue | 71,241 | 76,581 | 76,293 | 96,350 | $1,10,757$ |
| EBITDA | 6,117 | 6,867 | 5,798 | 8,961 | 10,965 |
| EBITDA Margin (\%) | 8.6 | 9.0 | 7.6 | 9.3 | 9.9 |
| APAT | 5,256 | 5,722 | 4,664 | 7,584 | 9,563 |
| EPS (Rs) | 15.9 | 17.3 | 14.1 | 22.9 | 28.9 |
| EPS (\% chg) | $(8.9)$ | 8.9 | $(18.5)$ | 62.6 | 26.1 |
| ROE (\%) | 13.1 | 13.6 | 10.4 | 15.2 | 16.9 |
| P/E (x) | 66.6 | 61.2 | 75.0 | 46.2 | 36.6 |
| EV/EBITDA (x) | 54.6 | 48.3 | 56.9 | 36.2 | 29.1 |
| P/BV (x) | 8.5 | 8.2 | 7.4 | 6.6 | 5.8 |
| Soure |  |  |  |  |  |

Source: Company, Emkay Research

| CMP | Target Price |
| :--- | ---: |
| Rs 1,058 | Rs 1,100 ( $\mathbf{1}$ ) |
| as of (February 15, 2021) | 12 months |
| Rating | Upside |
| HOLD (口) | $4.0 \%$ |


| Change in Estimates |  |  |
| :--- | ---: | ---: |
| EPS Chg FY21E/FY22E (\%) | $7 / 17$ |  |
| Target Price change (\%) | 46.7 |  |
| Target Period (Months) | 12 |  |
| Previous Reco | HOLD |  |
| Emkay vs Consensus |  |  |
| EPS Estimates |  |  |
| FY21E |  | FY22E |
| Emkay | 14.1 | 22.9 |
| Consensus | 13.9 | 21.5 |
| Mean Consensus TP (12M) | Rs 918 |  |
| Stock Details |  |  |
| Bloomberg Code | VOLT IN |  |
| Face Value (Rs) | 1 |  |
| Shares outstanding (mn) | 331 |  |
| 52 Week H/L | $1,132 / 427$ |  |
| M Cap (Rs bn/USD bn) | $350 / 4.82$ |  |
| Daily Avg Volume (nos.) | $22,09,481$ |  |
| Daily Avg Turnover (US $\$ \mathrm{mn})$ | 27.3 |  |


| Shareholding Pattern Dec '20 |  |
| :--- | ---: |
| Promoters | $30.3 \%$ |
| FIls | $14.6 \%$ |
| DIls | $37.4 \%$ |
| Public and Others | $\mathbf{1 7 . 8 \%}$ |


| Price Performance |  |  |  |  |
| :--- | ---: | ---: | ---: | ---: |
| (\%) | $\mathbf{1 M}$ | $\mathbf{3 M}$ | $\mathbf{6 M}$ | $\mathbf{1 2 M}$ |
| Absolute | 19 | 39 | 72 | 54 |
| Rel. to Nifty | 12 | 16 | 25 | $\mathbf{2 2}$ |

Relative price chart


This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

Naval Seth
naval.seth@emkayglobal.com
+912266242414
Abhijeet Singh
abhijeet.singh@emkayglobal.com
+91 2266121241
Sonali Shah
sonali.shah@emkayglobal.com
+91 2266242482

## Story in Charts

Exhibit 1: Volume growth in RACs and commercial refrigerators drives UCP revenues


Source: Company, Emkay Research

Exhibit 3: Strong volume growth helps sustain market share


Source: Company, Emkay Research
Exhibit 5: Strong execution seen in EMPS business


## Source: Company, Emkay Research

Exhibit 7: Order book sees improvement on inflows


[^0]Exhibit 2: Strong operating leverage with 235bps margin expansion


Source: Company, Emkay Research

Exhibit 4: RAC volume market share - annual


Exhibit 6: Legacy projects related provisioning hurt margins


Source: Company, Emkay Research
Exhibit 8: Strong order inflow signals pick up in broader economy


[^1]Exhibit 9: Strong EPS revenue growth of 46.4\% yoy


[^2]Exhibit 10: EBIT margin saw a 147bps dip in the quarter


Source: Company, Emkay Research

## Other highlights

## UCP segment

- Revenue growth of $39.8 \%$ yoy to Rs8.4bn was driven by volume growth of $40 \%$ (RAC $+43 \%$; Commercial refrigeration $+100 \%$; and Air-Coolers $+11 \%$ ). The RAC business market share stood at $26 \%$ in Dec'20 YTD.
- Focus on the inverter category with competitive pricing and larger number of SKUs has yielded strong results. Inverter growth was 75\% ahead of the previous year and now contributes more than $60 \%$ of all ACs sold vs. 49\% in the comparative period a year ago. That apart, Voltas has also achieved leadership position in the Inverter category, with an exit market share of $21.8 \%$ as of Dec'20. In the AC market, Voltas continues to be the leader with a market share of $26 \%$ YTD at multi-brand outlets.
- Air cooler performance was satisfactory, with 11\% yoy growth. Increased number of variants and SKUs, together with appropriate trade schemes, have helped secure a wider distribution footprint across the sub-dealer network. Based on Nov'20 exit numbers, Voltas now enjoys the No. 2 position, with a market share of $13.2 \%$.
- EBIT improvement was driven by better product mix amid cost efficiencies, coupled with lower holding cost of carry forward inventories. The EBIT margin expansion of 240bps yoy (at $12.5 \%$ ) saw improved EBIT of Rs1.04bn vs. Rs607mn in Q3FY21.


## EMPS segment

- The EMPS business saw strong execution with revenue growing $25.8 \%$ yoy to Rs10.16bn.
- EBIT stood at Rs322.2mn vs. Rs374mn in Q3FY20. EBIT margin contracted 146bps yoy to $3.2 \%$. The margin impact could be attributed to conservative time-based provisions and liquidity constraints on certain legacy projects.
- Order inflows for the quarter was Rs7bn from both Domestic and International markets. The carry forward order book for Domestic projects at Rs47.9bn contained a bouquet of orders across Water, HVAC, Rural Electrification and Urban infra activities. The international order book of Rs24.8bn represents MEP work, mainly across the UAE, Qatar and Oman.


## Volt-Bek

- The company successfully produced over 210,000 units of high-quality DC refrigerators. The focus is on maximizing production to meet increasing demand for DC refrigerators and plans are in place to start manufacturing frost-free refrigerators in the coming months, followed by top-load fully automatic washing machines and dishwashers.
- In terms of distribution, billing points have been scaled up to exceed 1,000 from 900 in the last quarter.
- Currently, both Voltas and Volt-Bek have joint presence in 195 EBOs vs. 90 in Q3FY20. Costs are well in line with the budget, and management is confident of meeting its targets, including that of $10 \%$ market share by 2024-25.

Exhibit 11: Actual vs. estimates (Q3FY21)

| (Rs mn) | Actual | Estimate (Emkay) | Consensus estimate (Bloomberg) | \% variation |  | Comment |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | Emkay | Consensus |  |
| Revenue | 19,946 | 17,037 | 16,551 | 17\% | 21\% | Beat was across the product categories |
| EBITDA | 1,459 | 1,141 | 1,156 | 28\% | 26\% | Better cost management led to operating leverage |
| EBITDA Margin | 7.3\% | 6.7\% | 7.0\% | 61 bps | 33 bps |  |
| PAT | 1,286 | 1,043 | 1,002 | 23\% | 28\% |  |

Source: Emkay Research

Exhibit 12: Quarterly financials

| Rs mn | Q3FY20 | Q4FY20 | Q1FY21 | Q2FY21 | Q3FY21 | YoY (\%) | QoQ (\%) | 9MFY21 | 9MFY20 | YoY (\%) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net Sales | 14,925.1 | 20,896 | 12,969 | 16,125 | 19,946 | 33.6 | 23.7 | 49,041 | 55,685 | (11.9) |
| Raw Material | 10655 | 14912 | 9082 | 11926 | 15041 | 41.2 | 26.1 | 36,050 | 40,637 | (11.3) |
| as \% of sales | 71.4 | 71.4 | 70.0 | 74.0 | 75.4 |  |  | 73.5 | 73.0 |  |
| Employee Cost | 1733.6 | 1775.7 | 1574.1 | 1432.2 | 1547.4 | (10.7) | 8.0 | 4,554 | 4,942 | (7.8) |
| as \% of sales | 11.6 | 8.5 | 12.1 | 8.9 | 7.8 |  |  | 9.3 | 8.9 |  |
| Other operating expenses | 1561 | 2288 | 1646 | 1787 | 1899 | 21.6 | 6.2 | 5,332 | 5,160 | 3.3 |
| as \% of sales | 10.5 | 10.9 | 12.7 | 11.1 | 9.5 |  |  | 10.9 | 9.3 |  |
| Total Expenditure | 13950 | 18976 | 12302 | 15146 | 18488 | 32.5 | 22.1 | 45,935 | 50,738 | (9.5) |
| EBITDA | 975 | 1920 | 668 | 980 | 1459 | 49.6 | 48.9 | 3,106 | 4,946 | (37.2) |
| Depreciation | 80.2 | 82.0 | 82.2 | 83.9 | 84.1 | 4.9 | 0.2 | 250 | 238 | 5.3 |
| EBIT | 895 | 1838 | 585 | 896 | 1375 | 53.6 | 53.4 | 2,856 | 4,709 | (39.3) |
| Other Income | 543 | 605 | 674 | 383 | 516 | (4.8) | 34.9 | 1,573 | 1,701 | (7.6) |
| Interest | 57 | 61 | 67 | 58 | 32 | (44.2) | (44.9) | 157 | 151 | 4.5 |
| Share of Profit and loss from associate | -187 | -195 | -117 | -71 | -201 |  |  | -388 | -492 |  |
| Exceptional Items | 0 | -20 | 0 | 0 | 0 |  |  | 0 | -492 |  |
| PBT | 1193 | 2167 | 1075 | 1150 | 1658 | 39.0 | 44.2 | 3,884 | 6,260 | (38.0) |
| Tax | 314 | 573 | 258 | 353 | 372 | 18.6 | 5.3 | 983 | 1,660 | (40.8) |
| PAT | 879 | 1595 | 818 | 797 | 1286 | 46.3 | 61.5 | 2901 | 4600 | (36.9) |


| Margins (\%) |  |  |  |  | (bps) | (bps) | (bps) |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Gross Margin | 28.6 | 28.6 | 30.0 | 26.0 | 24.6 | $(402)$ | $(145)$ | 26.5 |
| EBIDTA | 6.5 | 9.2 | 5.1 | 6.1 | 7.3 | 78 | 124 | 6.3 |
| EBIT | 6.0 | 8.8 | 4.5 | 5.6 | 6.9 | 89 | 134 | 5.8 |
| EBT | 8.0 | 10.4 | 8.3 | 7.1 | 8.3 | 8.5 | $(255)$ |  |
| PAT | 5.9 | 7.6 | 6.3 | 4.9 | 6.4 | 56 | 118 | 7.9 |
| Effective Tax rate | 26.3 | 26.4 | 24.0 | 30.7 | 22.4 | $(386)$ | 11.2 | $(332)$ |

Source: Company, Emkay Research

Exhibit 13: Quarterly segmental financials

| Rs mn | Q3FY20 | Q4FY20 | Q1FY21 | Q2FY21 | Q3FY21 | YoY (\%) | QoQ (\%) | 9MFY21 | 9MFY20 | YoY (\%) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| EMPS | 8,081 | 8,046 | 5,181 | 9,278 | 10,167 | 25.8 | 9.6 | 24,626 | 24,416 | 0.9 |
| EPS | 826 | 948 | 476 | 933 | 1,209 | 46.4 | 29.6 | 2,618 | 2,369 | 10.5 |
| UCP | 6,005 | 11,989 | 7,071 | 5,717 | 8,396 | 39.8 | 46.9 | 21,184 | 28,748 | (26.3) |
| Less: Intersegment | 42 | 198 | 21 | 52 | 68 | 62.6 | 30.6 | 140 | 45 |  |
| Income from operations | 14,871 | 20,784 | 12,708 | 15,876 | 19,704 | 32.5 | 24.1 | 48,287 | 55,488 | (13.0) |
| PBIT |  |  |  |  |  |  |  |  |  |  |
| EMPS | 374.2 | 112.9 | -392.8 | 229.8 | 322.2 | (13.9) | 40.2 | 159 | 1,591 | (90.0) |
| EPS | 231.0 | 269.4 | 196.7 | 288.0 | 320.4 | 38.7 | 11.3 | 805 | 723 | 11.3 |
| UCP | 606.8 | 1753.7 | 1095.6 | 631.1 | 1045.5 | 72.3 | 65.7 | 2,772 | 3,367 | (17.7) |
| Total PBIT | 1,212 | 2,136 | 900 | 1,149 | 1,688 | 39.3 | 46.9 | 3,737 | 5,681 | (34.2) |
|  |  |  |  |  |  |  |  |  |  |  |
| Less: Un-allocable expense | -38.5 | -112.1 | -243.0 | -59.1 | -2.3 | (94.0) | (96.1) | -304 | -237 | 28.7 |
| Operating Income | 1251 | 2248 | 1143 | 1208 | 1690 | 35.2 | 39.9 | 4040.9 | 5917.9 | (31.7) |
| Less: Interest Expense | 57 | 61 | 67 | 58 | 32 | (44.2) | (44.9) | 157 | 151 |  |
| Exceptional | 0 | -20 | 0 | 0 | 0 |  |  | 0 | -492 |  |
| PBT | 1193 | 2167 | 1075 | 1150 | 1658 | 39.0 | 44.2 | 3884 | 5276 | (26.4) |


| PBIT Margins (\%) |  |  |  |  |  | (bps) | (bps) |  |  | (bps) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| EMPS | 4.6 | 1.4 | (7.6) | 2.5 | 3.2 | (146) | 69 | 0.6 | 6.5 | (587) |
| EPS | 28.0 | 28.4 | 41.3 | 30.9 | 26.5 | (147) | (437) | 30.8 | 30.5 | 21 |
| UCP | 10.1 | 14.6 | 15.5 | 11.0 | 12.5 | 235 | 141 | 13.1 | 11.7 | 137 |
| Total PBIT | 8.2 | 10.3 | 7.1 | 7.2 | 8.6 | 42 | 133 | 7.7 | 10.2 | (250) |

Source: Company, Emkay Research
Exhibit 14: Key assumptions

| Revenue (Rs mn) | FY18 | FY19 | FY20 | FY21E | FY22E | FY23E |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| EMPS | 28,452 | 36,191 | 32,461 | 35,155 | 42,134 | 47,161 |
| yoy | 7\% | 27\% | -10\% | 8\% | 20\% | 12\% |
| Order Inflow | 35,862 | 35,331 | 60,581 | 30,291 | 37,863 | 43,543 |
| yoy | 28\% | -1\% | 71\% | -50\% | 25\% | 15\% |
| Order Book | 44,223 | 49,760 | 77,880 | 73,015 | 68,744 | 65,127 |
| yoy | 20\% | 13\% | 57\% | -6\% | -6\% | -5\% |
| EPS | 3,099 | 3,117 | 3,317 | 3,482 | 3,796 | 4,137 |
| yoy | -7\% | 1\% | 6\% | 5\% | 9\% | 9\% |
| UCP | 32,026 | 31,556 | 40,737 | 36,842 | 49,394 | 58,279 |
| yoy | 7\% | -1\% | 29\% | -10\% | 34\% | 18\% |
| Total Revenue | 63,577 | 70,863 | 76,515 | 75,480 | 95,323 | 1,09,577 |
| yoy | 6\% | 11\% | 8\% | -1\% | 26\% | 15\% |
| PBIT (Rs mn) |  |  |  |  |  |  |
| EMPS | 1,854 | 2,773 | 1,704 | 605 | 2,317 | 3,537 |
| \% Margin | 7\% | 8\% | 5\% | 2\% | 6\% | 8\% |
| EPS | 992 | 1,051 | 993 | 1,045 | 1,139 | 1,241 |
| \% Margin | 32\% | 34\% | 30\% | 30\% | 30\% | 30\% |
| UCP | 4,749 | 3,254 | 5,121 | 4,974 | 6,668 | 7,868 |
| \% Margin | 15\% | 10\% | 13\% | 14\% | 14\% | 14\% |
| Total PBIT | 7,595 | 7,077 | 7,817 | 6,623 | 10,124 | 12,646 |
| \% Margin | 12\% | 10\% | 10\% | 9\% | 11\% | 12\% |

Source: Emkay Research

With strong Q3 delivery on the revenue and UCP margin fronts, we have raised our estimates across segments in the range of $8-14 \%$ for FY21-23E. Consolidated revenue upgrade in the same period stands at $9-14 \%$. Better margin profile in the EMP business, along with revenues, is leading us to raise FY21-23E EBITDA by 16-22\%. In addition, we have lowered our WACC assumptions to $9.5 \%$, which is resulting in implied per-share value increasing to Rs84. The target multiple for the UCP business is also raised to $48 x$ from $40 x$ earlier.

Exhibit 15: Changes in estimates

| Particulars (Rs mn) | FY21E |  |  | FY22E |  |  | FY23E |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Old | New | \% Change | Old | New | \% Change | Old | New | \% Change |
| EMPS | 32,451 | 35,155 | 8.3\% | 37,035 | 42,134 | 13.8\% | 41,938 | 47,161 | 12.5\% |
| EPS | 3,151 | 3,482 | 10.5\% | 3,403 | 3,796 | 11.5\% | 3,675 | 4,137 | 12.6\% |
| UCP | 33,439 | 36,842 | 10.2\% | 44,792 | 49,394 | 10.3\% | 51,035 | 58,279 | 14.2\% |
| Total Revenue | 69,716 | 76,293 | 9.4\% | 86,063 | 96,350 | 12.0\% | 97,593 | 1,10,757 | 13.5\% |
| EBITDA | 5,020 | 5,798 | 15.5\% | 7,444 | 8,961 | 20.4\% | 8,783 | 10,965 | 24.8\% |
| EBITDA Margin \% | 7.2 | 7.6 | 40 bps | 8.7 | 9.3 | 65 bps | 9.0 | 9.9 | 90 bps |
| PAT | 4359 | 4664 | 7.0\% | 6471 | 7584 | 17.2\% | 7985 | 9563 | 19.8\% |
| EPS | 13.2 | 14.1 | 7.0\% | 19.6 | 22.9 | 17.2\% | 24.1 | 28.9 | 19.8\% |

Source: Emkay Research
Exhibit 16: SoTP-based valuation

| Market Cap | PAT | Multiple | Rs mn |
| :--- | ---: | ---: | ---: |
| EMPS | 2,681 | 15 | 40,212 |
| EPS | 941 | 10 | 9,408 |
| UCP | 5,963 | 48 | $2,86,226$ |
| Total Mcap | 9,585 |  | $\mathbf{3 , 3 5 , 8 4 5}$ |
| Number of Shares |  | 331 |  |
| Target Price |  | 1,016 |  |
| Value of VoltBek |  | 84 |  |
| Total Value (Rs) |  | $\mathbf{1 , 1 0 0}$ |  |

Source: Emkay Research

## Valuation charts



[^3]Exhibit 18: 1-year forward P/B band


Source: Bloomberg, Emkay Research

Exhibit 19: 1-year forward EV/EBITDA band


[^4]Key Financials (Consolidated)
Income Statement

| Y/E Mar (Rs mn) | FY19 | FY20 | FY21E | FY22E | FY23E |
| :--- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $\mathbf{7 1 , 2 4 1}$ | $\mathbf{7 6 , 5 8 1}$ | $\mathbf{7 6 , 2 9 3}$ | $\mathbf{9 6 , 3 5 0}$ | $\mathbf{1 , 1 0 , 7 5 7}$ |
| Expenditure | $\mathbf{6 5 , 1 2 4}$ | $\mathbf{6 9 , 7 1 4}$ | $\mathbf{7 0 , 4 9 5}$ | $\mathbf{8 7 , 3 9 0}$ | $\mathbf{9 9 , 7 9 2}$ |
| EBITDA | $\mathbf{6 , 1 1 7}$ | $\mathbf{6 , 8 6 7}$ | $\mathbf{5 , 7 9 8}$ | $\mathbf{8 , 9 6 1}$ | $\mathbf{1 0 , 9 6 5}$ |
| Depreciation | 240 | 320 | 342 | 360 | 387 |
| EBIT | $\mathbf{5 , 8 7 7}$ | $\mathbf{6 , 5 4 7}$ | $\mathbf{5 , 4 5 6}$ | $\mathbf{8 , 6 0 0}$ | $\mathbf{1 0 , 5 7 8}$ |
| Other Income | 1,863 | 2,306 | 2,230 | 2,410 | 2,620 |
| Interest expenses | 330 | 211 | 259 | 254 | 292 |
| PBT | $\mathbf{7 , 4 1 0}$ | $\mathbf{8 , 6 4 2}$ | $\mathbf{7 , 4 2 7}$ | $\mathbf{1 0 , 7 5 6}$ | $\mathbf{1 2 , 9 0 6}$ |
| Tax | 1,635 | 2,233 | 2,040 | 2,954 | 3,544 |
| Extraordinary Items | $(118)$ | $(512)$ | 0 | 0 | 0 |
| Minority Int./Income from Assoc. | $(518)$ | $(687)$ | $(724)$ | $\mathbf{( 2 1 9 )}$ | 201 |
| Reported Net Income | $\mathbf{5 , 1 3 9}$ | $\mathbf{5 , 2 1 1}$ | $\mathbf{4 , 6 6 4}$ | $\mathbf{7 , 5 8 4}$ | $\mathbf{9 , 5 6 3}$ |
| Adjusted PAT | $\mathbf{5 , 2 5 6}$ | $\mathbf{5 , 7 2 2}$ | $\mathbf{4 , 6 6 4}$ | $\mathbf{7 , 5 8 4}$ | $\mathbf{9 , 5 6 3}$ |

Balance Sheet

| Y/E Mar (Rs mn) | FY19 | FY20 | FY21E | FY22E | FY23E |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Equity share capital | 331 | 331 | 331 | 331 | 331 |
| Reserves \& surplus | 40,769 | 42,471 | 46,650 | 52,701 | 59,962 |
| Net worth | 41,100 | 42,802 | 46,981 | 53,032 | 60,293 |
| Minority Interest | 348 | 365 | 365 | 365 | 365 |
| Loan Funds | 3,147 | 2,179 | 2,676 | 3,484 | 4,005 |
| Net deferred tax liability | (993) | (715) | (715) | (715) | (715) |
| Total Liabilities | 43,601 | 44,631 | 49,307 | 56,167 | 63,949 |
| Net block | 2,968 | 3,351 | 4,572 | 4,575 | 4,752 |
| Investment | 23,859 | 23,433 | 23,433 | 23,433 | 23,433 |
| Current Assets | 47,178 | 53,786 | 56,264 | 70,882 | 84,034 |
| Cash \& bank balance | 3,211 | 3,084 | 5,764 | 11,921 | 17,671 |
| Other Current Assets | 8,550 | 9,769 | 9,175 | 9,223 | 9,257 |
| Current liabilities \& Provision | 30,560 | 36,201 | 35,224 | 42,985 | 48,533 |
| Net current assets | 16,618 | 17,585 | 21,040 | 27,897 | 35,502 |
| Misc. exp | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 43,601 | 44,631 | 49,307 | 56,167 | 63,949 |

## Cash Flow

| Y/E Mar (Rs mn) | FY19 | FY20 | FY21E | FY22E | FY23E |
| :--- | ---: | ---: | ---: | ---: | ---: |
| PBT (Ex-Other income) (NI+Dep) | $\mathbf{5 , 5 4 7}$ | $\mathbf{6 , 3 3 6}$ | $\mathbf{5 , 1 9 7}$ | $\mathbf{8 , 3 4 6}$ | $\mathbf{1 0 , 2 8 6}$ |
| Other Non-Cash items | 0 | 0 | 0 | 0 | 0 |
| Chg in working cap | $(6,993)$ | $(815)$ | $(775)$ | $(699)$ | $(1,856)$ |
| Operating Cashflow | $(3,214)$ | $\mathbf{4 , 6 2 5}$ | 2,983 | $\mathbf{5 , 3 0 8}$ | $\mathbf{5 , 5 6 5}$ |
| Capital expenditure | $(799)$ | $(809)$ | $(1,564)$ | $(364)$ | $(564)$ |
| Free Cash Flow | $(4,013)$ | 3,816 | $\mathbf{1 , 4 2 0}$ | $\mathbf{4 , 9 4 4}$ | $\mathbf{5 , 0 0 1}$ |
| Investments | 4,124 | 426 | 0 | 0 | 0 |
| Other Investing Cash Flow | $(1,261)$ | $(4,028)$ | 0 | 0 | 0 |
| Investing Cashflow | 3,927 | $\mathbf{( 2 , 1 0 5 )}$ | $\mathbf{6 6 7}$ | $\mathbf{2 , 0 4 7}$ | $\mathbf{2 , 0 5 7}$ |
| Equity Capital Raised | 0 | 0 | 0 | 0 | 0 |
| Loans Taken / (Repaid) | 1,724 | $(968)$ | 498 | 808 | 521 |
| Dividend paid (incl tax) | $(1,551)$ | $(1,572)$ | $(1,209)$ | $(1,751)$ | $(2,101)$ |
| Other Financing Cash Flow | $(181)$ | 104 | 0 | 0 | 0 |
| Financing Cashflow | $(339)$ | $(2,646)$ | $\mathbf{( 9 7 0 )}$ | $\mathbf{( 1 , 1 9 7 )}$ | $\mathbf{( 1 , 8 7 2 )}$ |
| Net chg in cash | 374 | $(127)$ | $\mathbf{2 , 6 8 0}$ | $\mathbf{6 , 1 5 8}$ | $\mathbf{5 , 7 4 9}$ |
| Opening cash position | 2,837 | 3,211 | 3,084 | 5,764 | $\mathbf{1 1 , 9 2 1}$ |
| Closing cash position | 3,211 | 3,084 | $\mathbf{5 , 7 6 4}$ | $\mathbf{1 1 , 9 2 1}$ | $\mathbf{1 7 , 6 7 1}$ |

Source: Company, Emkay Research

Key Ratios

| Profitability (\%) | FY19 | FY20 | FY21E | FY22E | FY23E |
| :--- | ---: | ---: | ---: | ---: | ---: |
| EBITDA Margin | 8.6 | 9.0 | 7.6 | 9.3 | 9.9 |
| EBIT Margin | 8.2 | 8.5 | 7.2 | 8.9 | 9.6 |
| Effective Tax Rate | 22.1 | 25.8 | 27.5 | 27.5 | 27.5 |
| Net Margin | 8.1 | 8.4 | 7.1 | 8.1 | 8.5 |
| ROCE | 18.4 | 20.1 | 16.4 | 20.9 | 22.0 |
| ROE | 13.1 | 13.6 | 10.4 | 15.2 | 16.9 |
| RoIC | 44.8 | 38.3 | 28.9 | 42.6 | 49.1 |
|  |  |  |  |  |  |
| Per Share Data (Rs) | FY19 | FY20 | FY21E | FY22E | FY23E |
| EPS | 15.9 | 17.3 | 14.1 | 22.9 | 28.9 |
| CEPS | 16.6 | 18.3 | 15.1 | 24.0 | 30.1 |
| BVPS | 124.2 | 129.4 | 142.0 | 160.3 | 182.3 |
| DPS | 4.0 | 4.0 | 3.7 | 5.3 | 6.4 |
|  |  |  |  |  |  |
| Valuations (x) | FY19 | FY20 | FY21E | FY22E | FY23E |
| PER | 66.6 | 61.2 | 75.0 | 46.2 | 36.6 |
| P/CEPS | 63.7 | 57.9 | 69.9 | 44.1 | 35.2 |
| P/BV | 8.5 | 8.2 | 7.4 | 6.6 | 5.8 |
| EV / Sales | 4.7 | 4.3 | 4.3 | 3.4 | 2.9 |
| EV / EBITDA | 54.6 | 48.3 | 56.9 | 36.2 | 29.1 |
| Dividend Yield (\%) | 0.4 | 0.4 | 0.3 | 0.5 | 0.6 |
|  |  |  |  |  |  |


| Gearing Ratio (x) | FY19 | FY20 | FY21E | FY22E | FY23E |
| :--- | ---: | ---: | ---: | ---: | ---: |
| Net Debt/ Equity | $(0.4)$ | $(0.4)$ | $(0.4)$ | $(0.5)$ | $(0.5)$ |
| Net Debt/EBIDTA | $(2.6)$ | $(2.6)$ | $(3.5)$ | $(2.9)$ | $(2.8)$ |
| Working Cap Cycle (days) | 68.7 | 69.1 | 73.1 | 60.5 | 58.8 |


| Growth (\%) | FY19 | FY20 | FY21E | FY22E | FY23E |
| :--- | ---: | ---: | ---: | ---: | ---: |
| Revenue | 11.2 | 7.5 | $(0.4)$ | 26.3 | 15.0 |
| EBITDA | $(7.7)$ | 12.3 | $(15.6)$ | 54.5 | 22.4 |
| EBIT | $(7.9)$ | 11.4 | $(16.7)$ | 57.6 | 23.0 |
| PAT | $(11.1)$ | 1.4 | $(10.5)$ | 62.6 | 26.1 |


| Quarterly (Rs mn) | Q3FY20 | Q4FY20 | Q1FY21 | Q2FY21 | Q3FY21 |
| :--- | ---: | ---: | ---: | ---: | ---: |
| Revenue | 14,925 | 20,896 | 12,969 | 16,125 | 19,946 |
| EBITDA | 976 | 1,920 | 668 | 980 | $(4,493)$ |
| EBITDA Margin (\%) | $\mathbf{6 . 5}$ | $\mathbf{9 . 2}$ | $\mathbf{5 . 1}$ | $\mathbf{6 . 1}$ | $\mathbf{( 2 2 . 5 )}$ |
| PAT | 880 | 1,595 | 818 | 797 | $(4,666)$ |
| EPS (Rs) | $\mathbf{2 . 7}$ | $\mathbf{4 . 8}$ | $\mathbf{2 . 5}$ | $\mathbf{2 . 4}$ | $\mathbf{( 1 4 . 1 )}$ |
| Source: Company, Emkay Research |  |  |  |  |  |
| Shareholding Pattern (\%) | Dec-19 | Mar-20 | Jun-20 | Sep-20 | Dec-20 |
| Promoters | 30.3 | 30.3 | 30.3 | 30.3 | 30.3 |
| FIls | 10.9 | 9.9 | 10.7 | 12.4 | 14.6 |
| DIIs | 38.2 | 39.6 | 38.9 | 38.9 | 37.4 |
| Public and Others | 20.6 | 20.2 | 20.1 | 18.3 | 17.8 |
| Sincer |  |  |  |  |  |

Source: Capitaline

RECOMMENDATION HISTORY TABLE

| Date | Closing <br> Price | TP | Period <br> (months) | Rating | Analyst |
| :--- | ---: | ---: | ---: | :--- | :--- |
| 09-Nov-20 | 791 | 750 | $12 m$ | Hold | Naval Seth |
| 18-Aug-20 | 645 | 608 | $12 m$ | Hold | Naval Seth |
| 02-Jun-20 | 558 | 502 | $12 m$ | Hold | Naval Seth |
| 07-Apr-20 | 485 | 470 | $12 m$ | Hold | Naval Seth |
| 03-Apr-20 | 473 | 470 | $12 m$ | Hold | Naval Seth |
| 16-Mar-20 | 603 | 724 | $12 m$ | Hold | Naval Seth |
| 13-Feb-20 | 686 | 724 | $12 m$ | Hold | Naval Seth |
| 10-Feb-20 | 682 | 724 | $12 m$ | Hold | Naval Seth |
| 16-Dec-19 | 679 | 624 | $12 m$ | Hold | Naval Seth |
| 19-Nov-19 | 713 | 624 | $12 m$ | Hold | Naval Seth |
| 08-Nov-19 | 694 | 624 | $12 m$ | Hold | Naval Seth |
| 23-Sep-19 | 671 | 623 | $12 m$ | Hold | Naval Seth |
| 18-Sep-19 | 631 | 604 | $12 m$ | Hold | Naval Seth |
| 11-Sep-19 | 633 | 604 | $12 m$ | Hold | Naval Seth |
| 08-Aug-19 | 598 | 604 | $12 m$ | Hold | Naval Seth |
| Source: Company, Emkay Research |  |  |  |  |  |

RECOMMENDATION HISTORY CHART



Analyst: Naval Seth

## Contact Details

naval.seth@emkayglobal.com

## +912266242414

## Sector

Consumer Durables, Media \&
Entertainment, SMID and Telecom

## Analyst bio

Naval holds an MBA in Finance and has more than 12 years of experience in equity research. His team currently covers 19 stocks spread across three different sectors.

Emkay Alpha Portfolio - Consumer Durables

| EAP sector portfolio | BSE200 <br> Weight | EAP <br> Weight | OW/UW <br> $\mathbf{( \% )}$ | OW/UW <br> (bps) | EAP Weight <br> (Normalised) |
| :--- | ---: | ---: | ---: | ---: | ---: |
| Company Name | $\mathbf{0 . 9 7}$ | $\mathbf{0 . 9 7}$ | $\mathbf{0 \%}$ | $\mathbf{0}$ | $\mathbf{1 0 0 . 0 0}$ |
| Amber Enterprises | 0.00 | 0.00 | NA | 0 | 0.00 |
| Blue Star | 0.00 | 0.00 | NA | 0 | 0.00 |
| Crompton Greaves CE | 0.22 | 0.23 | $4 \%$ | 1 | 23.50 |
| Dixon Technologies | 0.00 | 0.02 | NA | 2 | 2.32 |
| Havells India | 0.34 | 0.32 | $-5 \%$ | -2 | 33.01 |
| KEl Industries | 0.00 | 0.00 | NA | 0 | 0.00 |
| Polycab India | 0.03 | 0.03 | $5 \%$ | 0 | 3.04 |
| V-Guard Industries | 0.00 | 0.00 | NA | 0 | 0.00 |
| Voltas | 0.29 | 0.28 | $-3 \%$ | -1 | 29.12 |
| Whirlpool Of India | 0.09 | 0.09 | $-6 \%$ | -1 | 9.00 |
| Cash | 0.00 | 0.00 | NA | 0 | 0.00 |

Source: Emkay Research
*Not under coverage: Equal Weight
High Conviction/Strong Over Weight High Conviction/Strong Under Weight

## Sector portfolio NAV

|  | Base |  |  |  |  | Latest |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | 1-Apr-19 | 14-Feb-20 | 14-Aug-20 | 13-Nov-20 | 13-Jan-21 | 12-Feb-21 |
| EAP - Consumer Durables | 100.0 | 106.6 | 101.0 | 124.9 | 155.8 | 171.6 |
| BSE200 Neutral Weighted Portfolio (ETF) | 100.0 | 100.9 | 93.5 | 115.2 | 142.7 | 157.4 |

*Performance measurement base date $1^{\text {st }}$ April 2019
Source: Emkay Research
Price Performance (\%)

|  | $\mathbf{1 m}$ | $\mathbf{3 m}$ | $\mathbf{6 m}$ | $\mathbf{1 2 m}$ |
| :--- | :---: | :---: | :---: | :---: |
| EAP - Consumer Durables | $10.1 \%$ | $37.4 \%$ | $69.9 \%$ | $60.9 \%$ |
| BSE200 Neutral Weighted Portfolio (ETF) | $10.3 \%$ | $36.7 \%$ | $68.4 \%$ | $56.1 \%$ |

Source: Emkay Research
NAV chart
NAV


Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): Nifty

Please see our model portfolio (Emkay Alpha Portfolio): SMID
"Emkay Alpha Portfolio - SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals"

Emkay Rating Distribution

| Ratings | Expected Return within the next 12-18 months. |
| :--- | :--- |
| BUY | Over $15 \%$ |
| HOLD | Between $-5 \%$ to $15 \%$ |
| SELL | Below $-5 \%$ |

Completed Date: 16 Feb 2021 00:21:57 (SGT)
Dissemination Date: 16 Feb 2021 00:22:57 (SGT)
Sources for all charts and tables are Emkay Research unless otherwise specified.

## GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com
EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.
EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.
Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report
EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

- This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.
- Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. brokerdealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)
The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate ${ }^{1}$ does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests ${ }^{2}$ in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

[^5]
## COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of February 15 2021
2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of February 15, 2021
5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of $1 \%$ or more securities of the subject company at the end of the month immediately preceding the February 15, 2021
6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the February 15, 2021

## RESTRICTIONS ON DISTRIBUTION

| General | This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. |
| :---: | :---: |
| Australia | This report is not for distribution into Australia. |
| Hong Kong | This report is not for distribution into Hong Kong. |
| Indonesia | This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia. |
| Malaysia | This report is not for distribution into Malaysia. |
| Singapore | This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 63272288 for matters arising from, or in connection with the report. |
| Thailand | This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd. |
| United Kingdom | This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. <br> In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication. |
| Dubai International Financial Centre | This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, $6^{\text {th }}$ Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it. |
| United Arab Emirates | This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent. |
| United States | DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate. |
| Other jurisdictions | In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. |


[^0]:    Source: Company, Emkay Research

[^1]:    Source: Company, Emkay Research

[^2]:    Source: Company, Emkay Research

[^3]:    Source: Bloomberg, Emkay Research

[^4]:    Source: Bloomberg, Emkay Research

[^5]:    ${ }^{1}$ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst
    ${ }^{2}$ Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant

